Myriad Genetics (MYGN) Announces Accelerated $50M Share Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Myriad Announces $50 Million Accelerated Share Repurchase Program
November 19, 2018 7:05 AM ESTSALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (ASR) agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Â Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the companys board of directors.
We remain highly confident in the future growth prospects for the company and believe repurchasing shares at current levels will generate a... More
